Bamco Inc. NY Has $148.94 Million Stock Holdings in argenx SE (NASDAQ:ARGX)

Bamco Inc. NY lessened its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 3.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 242,178 shares of the company's stock after selling 8,126 shares during the quarter. Bamco Inc. NY owned 0.40% of argenx worth $148,939,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of ARGX. Wilmington Savings Fund Society FSB acquired a new stake in shares of argenx during the third quarter worth approximately $652,000. GAMMA Investing LLC increased its position in shares of argenx by 44.8% in the 4th quarter. GAMMA Investing LLC now owns 252 shares of the company's stock worth $155,000 after purchasing an additional 78 shares during the last quarter. Central Pacific Bank Trust Division acquired a new position in argenx in the fourth quarter worth about $615,000. Fulton Bank N.A. bought a new stake in argenx in the fourth quarter valued at about $226,000. Finally, Assenagon Asset Management S.A. lifted its holdings in argenx by 21.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 34,955 shares of the company's stock worth $21,497,000 after buying an additional 6,161 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ARGX shares. Oppenheimer upped their price target on argenx from $675.00 to $704.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Piper Sandler upped their target price on argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a report on Tuesday, January 7th. HC Wainwright reissued a "buy" rating and issued a $720.00 price target on shares of argenx in a report on Tuesday, April 8th. Citigroup upped their price objective on argenx from $681.00 to $796.00 and gave the stock a "buy" rating in a research note on Thursday, April 17th. Finally, William Blair reiterated an "outperform" rating on shares of argenx in a research note on Friday, February 28th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $699.28.

argenx Trading Down 6.3 %

ARGX stock traded down $41.54 on Tuesday, hitting $615.11. 476,926 shares of the company's stock traded hands, compared to its average volume of 310,514. argenx SE has a 1-year low of $352.77 and a 1-year high of $678.21. The stock has a market cap of $37.56 billion, a price-to-earnings ratio of -698.99 and a beta of 0.57. The stock has a fifty day moving average of $598.80 and a 200-day moving average of $612.99.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. On average, equities research analysts anticipate that argenx SE will post 3.13 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.